Clifford Chance
Clifford Chance advised Polpharma on financings in the aggregate amount of up to PLN 1.1 billion
1 July 2021
Clifford Chance advised Polpharma on financings in the aggregate amount of up to PLN 1.1 billion
Clifford Chance advised Zakłady Farmaceutyczne "Polpharma" S.A. in connection with a term and revolving facility agreement in the aggregate amount of up to PLN 800 million. The financing consortium consisted of the following banks: BNP Paribas Bank Polska S.A., European Bank for Reconstruction and Development, Santander Bank Polska S.A. and PKO Bank Polski S.A. The loan will contribute to long-term development of Polpharma including R&D projects and “Go Green" transformation aimed at minimizing the environmental and climate impact of the company's operations. We also advised the company on a financing in the amount of up to PLN 300 million granted by the European Investment Bank.
The financing provided by a consortium of banks will be made available for general corporate and working capital purposes and in order to refinance the group's existing bank debt.
The EIB's loan will be used to finance an RDI programme in several therapeutic areas, including cardio, diabetes, ophthalmic and respiratory diseases.
The team advising on the financings consisted of: Andrzej Stosio (Partner, Co-head of the Warsaw Banking and Finance Department), Anna Miernik (Senior Associate) and Natalia Karasiewicz (Associate).
